Among domestic players, he named Sun Pharma, Eris Lifesciences, Lupin, Cipla and Dr Reddy's as well positioned to benefit
Comparison of glycemic variability in Chinese T2DM patients treated with exenatide or insulin glargine: a randomized controlled trial
As of early 2026, no oral tirzepatide formulation has received FDA approval
The mitochondrial transporter family SLC25: identification, properties and physiopathology
Certain medications for blood pressure, thyroid conditions, or arrhythmias interact with GLP-1 receptor agonists in ways that affect cardiac rate and rhythm
Another Harvard-led study found a 29% increase in coronary heart disease risk for each 0.5-point increase in HbA1c above 5.0%. Those numbers matter even when results technically fall within the normal range